Hindustan Laboratories Limited, an Indian pharmaceutical company focused on manufacturing generic medicines for government institutions, has received observations from the Securities and Exchange Board of India (SEBI) for its proposed initial public offering (IPO). The IPO aims to raise funds through a total issue size of up to 14.1 million equity shares with a face value of ₹10 each. This includes a fresh issue of 5 million shares and an offer for sale (OFS) of 9.1 million shares by promoter Rajesh Vasantray Doshi. The net proceeds from the IPO will be allocated towards funding the company’s working capital needs and general corporate purposes. Hindustan Laboratories supplies its products across India to various government agencies, ensuring consistent brand identity and quality assurance. The company plans to list its shares on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). Investors are advised to consult with certified experts before making any investment decisions.